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Abstract 17 
Here, volumetric absorptive microsampling (VAMS), used for the measurement of cardiovascular 18 
drugs, is compared against conventional dried blood spot (DBS) card sampling to evaluate adherence 19 
to prescribed medication. Volumetric absorptive microsampling (VAMS) is an attractive alternative 20 
to plasma sampling for routine drug monitoring and potentially overcomes haematocrit issues 21 
associated with quantitative bioanalysis of conventional dried blood spots. A quantitative VAMS-22 
based LC-HRAM MS assay for atenolol, lisinopril, simvastatin and valsartan was developed and 23 
validated. The assay demonstrated acceptable linearity, selectivity, accuracy, precision, recovery and 24 
insignificant matrix effects with no impact of haematocrit on assay accuracy. Volunteers provided 25 
both VAMS and DBS 903 card samples (the current standard) to allow comparison of the two 26 
methods and demonstrate the potential utility of VAMS.  Analysis of VAMS samples correctly 27 
identified drugs in volunteers known to be adherent, and found no false positives from volunteers 28 
known to be taking no medication. There was a strong correlation between the two sampling 29 
systems confirming the utility of VAMS. Therapeutic drug monitoring (TDM) can assist clinicians in 30 
deciding how to proceed with treatment in the event of poor improvement in patient health. VAMS 31 
could offer a potentially more efficient method of sample collection, with fewer rejected samples 32 
than the DBS approach. 33 
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Highlights 47 
• VAMS was used for the quantification of four CVD therapy drugs to assess adherence. 48 
• LC-HRAM MS was used to quantify atenolol, lisinopril, simvastatin and valsartan. 49 
• VAMS showed no haematocrit effect because there is fixed volume sampling. 50 
• VAMS and DBS gave comparable drug concentrations for each individual volunteer. 51 
• The VAMS based assay has good potential for routine TDM for self-collected samples. 52 
 53 
Introduction 54 
Cardiovascular disease (CVD) is a major global killer, responsible for 17.7 million deaths every year 55 
[1]. In the UK, around 7 million people are affected with an estimated 155,000 deaths each year. 56 
CVD is a major economic burden with annual UK healthcare costs estimated at £11 billion [2]. The 57 
current medical care of CVD patients uses a combination of cardiovascular therapy drugs to treat 58 
high blood pressure and lower cholesterol [2]. The drug(s) selected and the dose(s) prescribed are 59 
structured to achieve and maintain a therapeutic drug concentration in the blood, with the goal of  60 
improving patient status [3]. However, it is reported that ˃50% of CVD patients do not adhere to 61 
their prescribed drug therapy [4, 5]. Medication nonadherence can result in poor clinical outcomes, 62 
hospital readmission with unnecessary additional care costs, and sometimes death.  Nonadherence 63 
is, therefore, a growing concern to clinicians, other healthcare professionals and health service 64 
providers [6,7]. 65 
Determination of therapeutic drug concentration in the blood can indicate the extent of the 66 
patient’s adherence to prescribed drug therapy [3]. The quantitative determination of cardiovascular 67 
drugs in plasma and serum using either liquid chromatography (LC) – tandem mass spectrometry 68 
(MS/MS) or LC-MS is documented [8-11]. However, these investigations required large biosample 69 
volumes (e.g., 1 – 10 mL), which can be a challenge to obtain from any patient in repeat routine 70 
testing scenarios, such as for therapeutic drug monitoring [3]. 71 
Dried blood spot (DBS) microsampling is an alternative approach to conventional liquid blood sample 72 
collection for quantitative bioanalysis and provides numerous advantages, for example, self-73 
sampling is possible, the sample has long-term stability and is readily transportable [12]. These 74 
advantages, in combination with improved analytical instrument capability, have led to a surge in 75 
the use of DBS in various healthcare applications [13, 14]. Our research group has reported on the 76 
potential for using a DBS-based micro-sampling assay to assess adherence to selected CVD 77 
medications [15-18]. However, it is acknowledged that DBS-based assays present critical issues and 78 
challenges that affect result quality; the primary issue being the influence of haematocrit (Hct) on 79 
the accuracy of the quantitative assay [19]. Abu-Rabie et al [19] identified two potential Hct-based 80 
assay biases, namely area bias and recovery bias. The area bias, where blood with high Hct is more 81 
viscous and leads to the formation of smaller blood spots on DBS cards, is well-documented in the 82 
literature [20]. The Hct based recovery bias is less well recognised, but has the potential to cause 83 
significant assay bias, particularly for DBS assays with lower (e.g., 60-40%) recovery [19]. The Hct 84 
range varies with age for adult males and females and is typically 40-54% and 36-48%, respectively 85 
[20]. This Hct-related uncertainty has prompted research into alternative microsampling platforms 86 
and has led to the development and introduction of novel collection devices, including volumetric 87 
absorptive microsampling (VAMS) [21]. VAMS microsampling devices were designed to provide the 88 
advantages of DBS, but circumvent its Hct-driven biases. VAMS facilitates the easy collection and 89 
drying of an accurate volume of blood (i.e., 10 µl or 20 µl) on an absorbent white tip attached to a 90 
plastic sample handler. This methodology eliminates the volumetric Hct effect associated with 91 
conventional DBS sampling when a punched disk is used, whereas VAMS collects a precise volume 92 
sample and the entire sample is extracted. VAMS has been used successfully in quantitative 93 
bioanalytical assays for therapeutic drug monitoring (TDM) and the determination of 94 
pharmacokinetic parameters [22]. 95 
Here, we evaluate the performance of VAMS using liquid chromatography – high resolution accurate 96 
mass (LC-HRAM) MS-based quantitative determination of four CVD drugs commonly prescribed in 97 
the UK. Additionally, we quantitatively compared the VAMS method against a previously published 98 
DBS-based [15] method on atenolol, lisinopril, simvastatin, and valsartan. The performance of VAMS 99 
was evaluated over a Hct range of 35-55% to confirm the absence of an Hct effect for each of the 100 
four drugs. This study describes a novel approach based on a VAMS based LC-HRAM MS assay for 101 
the simultaneous quantification of four CVD drugs in human blood with the potential for assessment 102 
of adherence. 103 
 104 
2. Materials & Methods 105 
2.1 Chemicals and Materials 106 
Atenolol (R-(+), 99%), atenolol d7, lisinopril, simvastatin and valsartan were purchased from Sigma–107 
Aldrich (Poole, UK). LC–MS grade acetonitrile, methanol and water were also obtained from Sigma–108 
Aldrich (Poole, UK). VAMS (Mitra®) devices (10 µL tip size) were purchased from Neoteryx (Torrance, 109 
CA, USA). 903 specimen collection paper, polyethylene bags, microcentrifuge tubes (1.5 mL), pipette 110 
tips and volumetric pipettes were all purchased from Fisher Scientific (Loughborough, UK). 111 
Autosampler vials with 250 µL inserts, vial caps and formic acid were obtained from Agilent 112 
Technologies (Cheshire, UK). Heparin-coated blood collection tubes were purchased from 113 
International Scientific Supplies Ltd. (Bradford, UK).  114 
Both the collection of fresh blank blood and VAMS and DBS samples from informed volunteers 115 
received ethical approval from the De Montfort University Research Ethics Committee.  Informed 116 
consent was obtained from all participants following the provision of participant information 117 
leaflets. 118 
2.2 Preparation of standard stock and working solutions for the four cardiovascular drugs  119 
Standard stock solutions of atenolol, lisinopril, simvastatin and valsartan were prepared at a 120 
concentration of 1mg/mL in methanol. Multicomponent working solutions for each target drug were 121 
freshly prepared by diluting the stock solutions with methanol/water (i.e., 70:30, v/v). 122 
Spiked blood standards were prepared by spiking different samples of 950 µL fresh blank blood with 123 
50 µL of one of each multicomponent working solution to yield final blood target drug 124 
concentrations of 10, 20, 50, 100, 200, 500, 1000 and 1500 ng/mL for atenolol, 0.1, 0.5, 1, 5, 10, 25, 125 
50, 100 ng/mL for lisinopril and simvastatin and 50, 100, 250, 500, 1000, 2000, 3000, 4000 ng/mL for 126 
valsartan. The Hct of the blood was 45%. 50 µL of methanol/water (70:30, v/v) was spiked into 950 127 
µL of fresh blank blood to produce a zero (blank) blood sample. An internal standard (IS), atenolol 128 
D7, stock solution was prepared in methanol at a concentration of 10 µg/mL and diluted further with 129 
methanol/water (70:30, v/v) to produce an extraction solvent containing 20 ng/mL of IS.  130 
 131 
2.3 Preparation of calibration standards and validation samples  132 
VAMS calibration samples were prepared following the manufacturer’s instructions using the 10 µL 133 
tip size devices. The upper part of the tip was dipped into a volume of spiked whole blood and blank 134 
blood. Care was taken not to completely immerse the tip into the blood in order to prevent 135 
overfilling. 136 
DBS calibration samples were prepared as detailed in our previously published work [15]. 137 
2.4 Solvent extraction of analytes from VAMS and DBS 138 
Each VAMS tip was separated from the handler and transferred to a 1.5 mL microcentrifuge tube. A 139 
300 µL volume of methanol containing IS (20 ng/mL of atenolol D7) was used for the extraction of 140 
the target drugs because of its optimum extraction efficiency and reduced interference, as shown in 141 
previously published work using DBS [15]. Tubes were vortexed for 1 minute, sonicated for 30 142 
minutes in a temperature controlled ultrasonic bath at 40°C and centrifuged at 13200 rpm for 10 143 
minutes. 270 µL of each supernatant was transferred into a new microcentrifuge tube and dried 144 
under a gentle stream of nitrogen gas. Dried residue was reconstituted with 150 µL of 145 
methanol/water (40:60, v/v) containing 0.1% formic acid. The final extracts were transferred into 146 
auto-sampler vials for LC-HRAM MS analyses.  147 
For the 903 sampling paper 30 µL of each prepared standard was spotted onto the sampling paper 148 
and allowed to dry for at least 3 hours. Solvent extraction of target analytes from an 8 mm punched 149 
disc was carried out using the protocol detailed by Bernieh et al [15].   150 
  151 
2.5 LC-HRAM MS conditions 152 
LC-HRAM MS analyses were performed on an Agilent 1290 LC on-line to an Agilent G6530A QTOF 153 
mass spectrometer following the previously described conditions with DBS samples [15]. 154 
2.6 Validation studies 155 
To demonstrate that the developed bioanalytical method was fit for purpose, validation experiments 156 
were conducted in accordance with international guidelines [23, 24]. The validation process includes 157 
an assessment of the selectivity, linearity, sensitivity, intra and inter-assay accuracy and precision, 158 
limit of quantification (LOQ), matrix effects, and Hct effects for the analytical process. The stability of 159 
atenolol, lisinopril, simvastatin and valsartan for extended periods within the analytical procedure 160 
were also examined. These experiments were carried out using appropriate low, medium and high 161 
concentrations of each analyte in the manner detailed for the DBS samples by Bernieh et al [15]. 162 
2.6.1 Selectivity 163 
Conventionally, in analyses of this type, selectivity is obtained via the use of multiple reaction 164 
monitoring where the characteristic fragmentation pathways have been previously identified. In this 165 
work, the accurate mass of the target analyte ion, measured to within 5 ppm, was used to 166 
demonstrate the necessary selectivity. This was achieved by comparison of data from blank VAMS 167 
tips and tips spiked with the analytes. The extracted ion chromatograms for the protonated species 168 
of atenolol (m/z 267.1703), lisinopril (m/z 406.2336) and valsartan (m/z 436.2343) and the sodium 169 
adduct for simvastatin (m/z 441.2611) were used for this comparison. 170 
2.6.2 Linearity and sensitivity 171 
Calibration standards were prepared in replicate (n = 6) and analysed on three separate days. A 172 
calibration plot for each Target Analyte/IS peak area ratio against nominal analyte concentration was 173 
produced and an equally-weighted linear regression was applied. A signal-to-noise ratio of ≥ 10 was 174 
used in order to determine the limit of quantification (LOQ) for atenolol, lisinopril, simvastatin and 175 
valsartan in the VAMS extracts. The coefficient of variation at the (LOQ) was determined for each 176 
target drug (n = 6) and was shown to be within the ≤20% limit. 177 
2.6.3 Accuracy and precision 178 
The inter- and intra-day accuracy and precision of the reported methodology was assessed by 179 
replicate (n = 6) analyses of quality control (QC) samples at the low, medium and high 180 
concentrations for each drug. Accuracy was expressed as the relative error (RE%) and precision as 181 
the coefficient of variation (CV%). With reference to international guidelines [23,24], a RE and CV of 182 
≤15% was considered acceptable.  183 
 2.6.4 Matrix effects 184 
The matrix effects on drug detection at appropriate low, medium and high concentrations, due to 185 
constituents within VAMS were assessed in the manner detailed by Bernieh et al [15] using blood 186 
samples collected from three different sources. Replicate (n = 6) samples of the four target analytes 187 
spiked in blank blood extracts from VAMS and 903 DBS sampling paper [15] to represent low, 188 
medium and high concentrations were prepared. The prepared samples were compared with 189 
standards of equal concentration spiked into methanol/water (40:60%, v/v) containing 0.1% formic 190 
acid for the four target analytes. The matrix effect was calculated using the formula (B/A -1) x 100. 191 
Where A represents the ratio of the Target Analyte/IS response from analyte spiked into pure 192 
solvent and B represents the ratio of the Target Analyte/IS response from analyte spiked into 193 
extracted blank whole blood. 194 
2.6.5 Determination of the recovery of the four target analytes from VAMS 195 
The extraction efficiency, or the recovery, of atenolol, lisinopril, simvastatin and valsartan from 196 
spiked VAMS tips was determined using the DBS-based methods detailed in Bernieh et al [15]. It was 197 
determined using replicate (n=6) samples prepared at the low, medium and high concentrations for 198 
the four target drugs from spiked VAMS. Recovery was determined by comparing the ratios of 199 
analyte to IS response from VAMS extracts with those obtained from blank blood spot extracts 200 
spiked with solution standards of equal concentration. The recovery was calculated using the 201 
formula: % recovery = (analyte-to-IS response of VAMS extract)/(analyte to IS response of post 202 
extraction blank VAMS spiked extract) x 100. 203 
2.6.6 Evaluation of the effects of different Hct levels 204 
The effects of different Hct levels on the DBS assay performance have been previously evaluated at 205 
the low, medium and high concentrations of each target drug (n = 6) with an adjusted Hct of 35, 45 206 
and 55% [15]. In the present study, the performance of VAMS was evaluated over the same Hct 207 
range for the four target drugs.  The Hct reference samples were prepared from blank human whole 208 
blood centrifuged at 10,000 g for 12 minutes and the plasma generated transferred into a clean 209 
microcentrifuge tube. The red blood cell suspension and plasma were mixed in proportions of 210 
(35:65, v/v), (45:55, v/v) and (55:45, v/v) to achieve an adjusted whole blood Hct of 35%, 45% and 211 
55%, respectively [25]. These were used to prepare calibration samples on both 903 DBS sampling 212 
paper [15] and the VAMS device for the four target analytes at the blank, low, medium and high 213 
concentration ranges.  214 
2.6.7 Sample stability on VAMS  215 
The stability of VAMS samples during storage for eight weeks at room temperature was determined 216 
by analysing replicate (n=6) VAMS extracts spiked with atenolol, lisinopril, simvastatin and valsartan 217 
at low, medium and high concentrations. This was to investigate if batch-wise preparation and 218 
subsequent storage would be possible.  219 
2.7 Application of method to volunteer VAMS and DBS samples 220 
The developed LC–HRAM MS analytical methodology was applied to a series of both VAMS and DBS 221 
samples collected from two different groups of informed volunteers. The first group of volunteers 222 
were all receiving a course of one or more of the target drugs atenolol, lisinopril, simvastatin and 223 
valsartan. The second group of volunteers were not prescribed any of the target drugs and the 224 
samples collected from these volunteers were used as reference blanks for the analytical process. 225 
Where relevant, volunteers were asked to specify the time delay between taking their medication 226 
and the time the sample was collected. Typically, four DBS samples (i.e., 4 x 30 µL), and four VAMS 227 
samples (i.e., 4 x 10 µL) were collected as quickly as possible from each volunteer. These were 228 
collected from either one or two fingerprick samples per patient, as necessary. 229 
Prior to sample collection, it was confirmed that each volunteer had read the information sheet and 230 
was willing to progress by signing the consent documentation. 231 
2.8 DBS Summary 232 
DBS samples were prepared, collected and analysed as detailed in the previously published work by 233 
Bernieh et al[15]. 234 
 235 
3. Results and Discussion  236 
3.1 Selectivity 237 
Using the accurate masses determined for the four cardiovascular drugs and internal standard, 238 
selectivity was evaluated by comparing extracted ion chromatograms (EICs) derived at the limit of 239 
quantification from a VAMS calibration standard for each target analyte and the internal standard, 240 
with those obtained from blank VAMS samples. Selectivity enhancement was obtained by narrowing 241 
the m/z extraction window, as demonstrated previously [16]. Using a 5 ppm window for each target 242 
drug gave the most intense signal with no other interfering compounds and, therefore, improved 243 
selectivity. Representative EICs at the LOQ for each analyte and internal standard are shown in 244 
Figure 1(a) – (e). The protonated molecule [M+H]+ gave a high response for atenolol at m/z 245 
267.1703, lisinopril at m/z 406.2336 and valsartan at m/z 436.2343. The sodium adduct ion [M+Na]+ 246 
showed the highest signal intensity for simvastatin at m/z 441.2611. The DBS based LC-HRAM MS 247 
method also showed strong selectivity, as the EICs revealed no interfering peaks at the retention 248 










Figure 1. Representative LC-HRAM MS extracted ion chromatograms of a blank VAMS tip extract (red) and a 259 
calibration standard at the LLOQ spiked with the four target drugs (black). A narrow mass extraction window (5 260 
ppm) was used for (a) atenolol at m/z 267.1703 (b) lisinopril at m/z 406.2336 (c) simvastatin at m/z 441.2611 261 
(d) valsartan at m/z 436.2343 (e) atenolol d7 (internal standard) at m/z 274.2143.   262 
 263 
3.2 Linearity and sensitivity 264 
The calibration plots for the four target analytes in VAMS were generated in replicate (n = 6) using a 265 
plot of Target Analyte/IS peak area ratio against nominal analyte concentration. An equally weighted 266 
linear regression was applied and the data (i.e., slope, intercept and the mean correlation coefficient 267 
R2) is presented in Table 1. Back calculations indicated a relative error of less than 15% (typically 268 
between 2 and 10%) over the appropriate calibration range for each drug. The limit of quantification 269 
(LOQ) with a signal to noise ratio of ≥10 and the required assay accuracy and precision was 10 ng/mL 270 
for atenolol, 0.1 ng/mL for lisinopril, 0.1 ng/mL for simvastatin and 50 ng/mL for valsartan in whole 271 
dried blood.  272 
 273 
Table 1. Linearity and sensitivity data for the four cardiovascular drugs 274 
Drug Range (ng/mL) y = ax + b R2 LOQ (ng/mL) 
Atenolol 10 - 1500 y = 0.0074x - 0.136 0.992 ± 0.001 10 
Lisinopril 0.1 - 100 y = 0.0013x + 0.021 0.985 ± 0.004 0.1 
Simvastatin 0.1 - 100 y  = 0.016x + 0.215 0.988 ± 0.003 0.1 
Valsartan 50 - 4000 y = 0.006x + 0.125 0.992 ± 0.001 50 
 275 
3.3 Accuracy and precision 276 
The accuracy and precision of the developed LC-HRAM MS method were determined by intra- and 277 
inter-day replicate analyses of six spiked VAMS QC samples containing the four target analytes at the 278 
low, medium and high concentration levels on three separate days. Accuracy was expressed as the 279 
mean relative error (RE %) and precision was expressed as the coefficient of variation (CV %) and 280 
data obtained for both were within the predefined 15% limit [23, 24] for all concentrations in each 281 
run for all the target drugs. The overall variation in data between runs was also ≤15% for all target 282 
drugs. A summary of the results is presented in Table 2. 283 
Table 2. Intra- and inter-day accuracy and precision data for the four target cardiovascular drugs in VAMS 284 
extracts (n = 6 at each concentration level, for 3 days) 285 
       Coefficient of variation (%) 
Drug Nominal conc. (ng/mL) 
Measured conc. 
(ng/mL) Accuracy (RE) % Intra day Inter day 
Atenolol 50 51.58 3.16 1.71 2.07 
 500 499.02 -0.20 6.04 0.97 
 1500 1518.72 1.25 2.99 1.71 
Lisinopril 1 1.06 4.49 5.66 2.53 
 25 25.16 0.63 9.18 1.75 
 100 100.32 0.32 7.82 0.75 
Simvastatin 1 1.05 5.18 7.28 0.97 
 25 25.15 0.59 6.25 1.30 
 100 99.84 -0.16 5.16 0.22 
Valsartan 250 250.34 0.14 5.27 1.19 
 2000 1971.85 -1.41 3.05 1.55 
 4000 4086.14 2.15 7.76 0.29 
 286 
3.4 Matrix effect 287 
Matrix effect caused by blood constituents, as well as from the VAMS device material itself [26], was 288 
examined to ensure that the sensitivity and precision of the developed method was not 289 
compromised. The matrix effect data obtained for each target analyte investigated at the low, 290 
medium and high concentration levels of the calibration curve is presented in Table 3. No significant 291 
(i.e., >10%) matrix effects on the analyte signal due to endogenous components of blood or the 292 
VAMS sampling material was observed at the three tested concentrations of each target drug. These 293 
results demonstrate the robustness of the extraction procedure, and of the ionisation mechanism, 294 
for these target analytes. Comparison of the results from 903 sampling paper [15] versus VAMS 295 
revealed mean matrix effects for lisinopril and simvastatin were significantly higher for 903 sampling 296 
paper. This could be attributed to the extraction of constituents from within the 903 sampling paper 297 
that cause ionisation competition with lisinopril and simvastatin at the ESI source of the MS.  298 
 299 
Table 3. Matrix effect results obtained for the four target drugs studied at the low, medium and high 300 
concentration levels using VAMS (n = 6 at each concentration level) 301 
Drug Nominal conc. (ng/mL) Matrix effect % (mean) Precision (CV%) 
Atenolol 50 0.88 1.34 
 500 3.39 2.52 
 1500 2.20 3.81 
Lisinopril 1 0.99 2.74 
 25 1.46 3.52 
 100 3.66 4.76 
Simvastatin 1 2.70 3.56 
 25 0.66 2.86 
 100 0.51 2.80 
Valsartan 250 -1.17 5.87 
 2000 1.01 0.02 
 4000 0.99 0.08 
 302 
3.5 Recovery 303 
Mean extraction recoveries of atenolol, lisinopril and simvastatin, and valsartan at the low, medium 304 
and high concentration levels of the calibration curve were 102%, 88%, 67% and 47%, respectively, 305 
from VAMS, and  89%, 88%, 68% and 96%, respectively, from 903 paper reported by Bernieh et al 306 
[15]. Possible reasons for the difference may be poor extraction of valsartan from the VAMS 307 
substrate or poor uptake of valsartan on the VAM absorptive tip. Recovery data from VAMS for each 308 
target analyte at the low, medium and high concentration levels is summarised in Table 4.  309 
Table 4 Recovery data for atenolol, lisinopril, simvastatin and valsartan extracted from VAMS at the low, 310 
medium and high concentration levels (n = 6 at each concentration level) 311 
Drug Nominal conc. (ng/mL) Recovery (%) Standard Deviation (SD) Precision (CV) 
Atenolol 50 103.31 6.36 5.61 
 500 106.17 2.65 2.34 
 1500 98.95 1.26 1.28 
Lisinopril 1 88.71 11.97 13.40 
 25 84.16 11.33 9.92 
 100 91.66 9.43 9.46 
Simvastatin 1 62.87 13.18 8.09 
 25 71.95 6.06 8.42 
 100 66.94 1.91 2.85 
Valsartan 250 39.89 5.80 3.82 
 2000 53.02 3.68 1.47 
 4000 48.44 2.55 2.43 
 312 
3.6 Haematocrit (Hct) evaluation 313 
The VAMS device has been reported to be independent of the Hct effect [27-29]. To confirm this, the 314 
influence of Hct on assay performance for the quantitative analysis of atenolol, lisinopril, simvastatin 315 
and valsartan was evaluated at the low, medium and high concentrations with an adjusted Hct of 35, 316 
45 and 55% to cover the range for the target population. Concentrations of extracts were 317 
determined using a linear regression equation generated from calibration data produced from 318 
standards prepared with the 45% Hct on VAMS. The results for the Hct investigation are presented in 319 
Table 5 and show that the VAMS device delivered accuracy (RE%) and precision (CV%) values within 320 
the pre-defined limit of ≤ 15% [20] at all Hct levels for each tested analyte concentration. As 321 
expected for VAMS, the differences between the Hct levels are much reduced in comparison with 322 
previously published work using DBS [15]. This demonstrates that quantitative analytical data 323 
collected on the VAMS device is not likely to be affected by inter-individual variability in Hct values 324 
for the Hct range investigated for the four target analytes. 325 
Table 5. Influence of Hct on the accuracy (RE %) of analyte quantification for VAMS presented as the difference 326 
from the Analyte/Internal Standard peak area ratio at the 45% Hct level. Precision (CV %) values for each 327 
tested concentration are shown in brackets (n = 6 at each concentration and Hct level) 328 
    Haematocrit (Hct) 
Drug Nominal conc. (ng/mL) 35% 45% 55% 
Atenolol 50 -6.52% (4.03) Normalized (7.15%) -5.80 (4.13) 
 500 5.19% (4.27) Normalized (4.38%) 5.10 (3.15) 
 1500 -1.13 (8.45) Normalized (4.72%) -2.19 (4.74) 
Lisinopril 1 -0.93% (10.03%) Normalised (13.44%) 2.93% (13.60%) 
 25 4.35% (10.17%) Normalised (3.37%) 3.65% (8.45%) 
 100 -5.90% (9.32%) Normalised (4.64%) -0.95% (3.89%) 
Simvastatin 1 1.13% (3.68%) Normalised (8.16%) -0.21% (9.89%) 
 25 5.03% (6.08) Normalised (3.7%) -2.70% (6.6%) 
 100 -2.42% (2.9%) Normalised (3.2%) -5.70% (4.6%) 
Valsartan 250 -1.45% (2.28%) Normalised (1.15%) -1.05% (2.07%) 
 2000 -0.52% (3.37%) Normalised (3.48%) -2.81% (3.08%) 
 4000 -0.43% (3.97%) Normalised (2.61%) -0.98% (2.23%) 
 329 
3.7 Stability 330 
The results shown in Table 6 demonstrate that the spiked samples of the selected drugs were stable 331 
in VAMS for 8 weeks storage at room temperature. This implies that VAMS microsampling 332 
methodology could be applicable in resource limited areas where samples may have to be collected 333 
in remote areas and there is a time delay before analysis can be completed. 334 
 335 
Table 6. Accuracy, precision and quantification of the LC-HRAM MS VAMS assay at the low, medium and high 336 
concentrations for atenolol, lisinopril, simvastatin and valsartan after 8 weeks of storage at room temperature 337 
(n = 6 at each concentration level) 338 
Drug Concentration in whole blood (ng/mL) 
Mean concentration 
found ±SD (ng/mL) (n=6) 
Accuracy 
(RE%) Precision (CV%) 
Atenolol 50 55.71 ± 2.34 11.42 4.21 
 500 523.31 ± 46.34 4.66 8.85 
 1500 1516.29 ± 82.00 1.09 5.41 
Lisinopril 1 0.99 ± 0.06 -1.01 6.41 
 25 27.05 ± 3.66 8.19 13.55 
 100 107.65 ± 10.07 7.65 9.36 
Simvastatin 1 1.08 ± 0.10 7.96 9.35 
 25 25.35 ± 1.82 1.39 7.19 
 100 94.20 ± 7.30 -5.80 7.75 
Valsartan 250 253.57 ± 30.06 1.43 11.86 
 2000 1921.63 ± 19.91 -3.92 1.04 
 4000 4039.78 ± 173.14 5.99 8.80 
 339 
3.8 Application of method to volunteer VAMS samples and comparison with DBS drug 340 
concentrations 341 
The developed and validated LC-HRAM MS method was successfully applied to the quantitative 342 
analysis of atenolol, lisinopril, simvastatin and valsartan for VAMS samples obtained from volunteers 343 
undergoing cardiovascular drug therapy treatment with one or more of the target drugs. These 344 
volunteer VAMS samples were collected opportunistically after a supposedly single dose of the 345 
target drug(s). A series of blank control VAMS samples were also taken from healthy volunteers not 346 
prescribed any of the target drugs, and analysed. The requirements for a bioanalytical method to 347 
monitor adherence to prescribed pharmacotherapy are to be able to determine the residual levels of 348 
drug up to 24 hours after the initial dose and to ascertain if the calculated drug levels are within the 349 
therapeutic window [3]. VAMS samples were self-collected from seventeen volunteers and were 350 
analysed with the developed LC-HRAM MS method; the VAMS concentrations obtained are shown in 351 
Table 7. 352 
 353 
Table 7. VAMS concentrations compared with DBS concentrations [15, 30] of the studied CVD drugs from 354 
volunteers prescribed one or more of the CVD drugs investigated 355 
N Sex Administered Drug Time after Oral intake (hrs) 
VAMS Concentration 
(ng/mL) ± (s.d) 
DBS Concentration 
(ng/mL) ± (s.d) 
1 M Valsartan 160mg 4 503.11 ± 5.12 493.72 ± 8.78 
2 F Simvastatin 20mg 13 2.81 ± 0.30 2.90 ± 0.77 
3 F Simvastatin 20mg 15 1.44 ± 1.19 1.79 ± 0.74 
4 M Valsartan 160mg 4 412.31 ± 11.68 407.16 ± 14.73 
5 M Simvastatin 40mg 6 < LOQ < LOQ 
6 M Lisinopril 20mg ? 29.59 ± 5.31 37.02 ± 8.59 
7 M Lisinopril 20mg 3.5 7.94 ± 1.35 8.02 ± 3.68 
8 M Simvastatin 20mg 10 1.29 ± 0.86 1.32 ± 0.42 
9 M Simvastatin 20mg 11 0.69 ± 0.77 0.85 ± 0.55 
10 M Valsartan 80mg 4 136.45 ± 2.62 131.49 ± 0.88 
11 M Atenolol 100mg 13 254.16 ± 5.37 248.30 ± 9.12 
12-14 F Controls - None N/A ˂LOQ ˂LOQ 




Figure 2. Bland-Altman plot comparing VAMS and DBS concentrations for atenolol, lisinopril, simvastatin and 359 
valsartan in volunteer samples.  360 
 361 
The drug concentrations found for VAMS were also compared to those obtained by DBS [15, 30] 362 
from the same volunteers, sampled at approximately the same time. The volunteer samples are 363 
“dynamic in vivo” samples obtained from a constantly changing drug pharmacokinetics environment 364 
within the body. To compare the two microsampling methods we used a Bland Altman plot (Figure 365 
2), which showed good concordance in the drug concentrations for VAMS and DBS because the 366 
difference was less than 2 SD from the mean. The results confirmed acceptable reproducibility 367 
between the two microsampling methods and demonstrate that the microsampling methodologies 368 
produce comparable quantitative results. However, significant differences in both patient ease-of-369 
use and cost of the sampling device should be considered before use in routine applications. 370 
Adherence to a prescribed drug therapy is indicated by the drug level in the blood being between 371 
the published Cmax concentration and 5.25% of Cmax i.e. the drug concentration after 5 half-lives, 372 
when it is considered to be therapeutically inactive. Conversely, non-adherence is indicated by  373 
absence of the drug in the volunteer’s blood sample or if the level is outside its therapeutic window 374 
[3]. On this basis, the results showed that for all volunteers, except volunteer 5, the calculated drug 375 
levels indicated adherence to prescribed drug therapy. For volunteer 5, there was no detectable 376 
simvastatin after 6 hours following oral intake. In vivo, simvastatin hydrolyses to simvastatin acid 377 
and the collected HRAM MS data for volunteer 5 was therefore re-interrogated for the [M+H]+ and 378 
[M+Na]+ ions for simvastatin acid at m/z 437.2898 and m/z 459.2727, which were shown not to be 379 
present. For volunteer 3 the experiments show that simvastatin can be measured at m/z 441.2611 380 
directly up to 15 hours after administration, indicating that the levels are within the limit of 381 
quantification of the assay at this time period.  382 
Volunteer feedback was obtained on their experience using self-sampling with VAMS and 903 paper 383 
and particularly regarding ease of use of both microsampling methods. All volunteers commented 384 
that it was easier and quicker to self-collect a micro-volume blood sample with VAMS. This 385 
advantage could translate in the adoption of this methodology and enhance the implementation of 386 
TDM in routine clinical practice [31]. 387 
 388 
4. Conclusion 389 
The feasibility of a VAMS based LC-HRAM MS method for the simultaneous quantification of 390 
atenolol, lisinopril, simvastatin and valsartan in 10 µL of whole has been demonstrated. The LC-391 
HRAM MS method developed was rapid, in terms of instrument time, and provided the sensitivity 392 
required for the determination of the four target cardiovascular drugs. The method was validated 393 
following international guidelines and has shown to be precise and accurate at all tested 394 
concentrations and also exhibited appropriate specificity and linearity. The VAMS samples were 395 
shown to be stable at room temperature for at least 8 weeks. This offers the possibility of batch- 396 
wise preparation and also allows time for the transport of samples to laboratories with appropriate 397 
analytical facilities. As expected, the target drug concentrations from the VAMS samples were not 398 
influenced by Hct. These advantages indicate VAMS, therefore, has great potential for routine 399 
therapeutic adherence monitoring by home sampling, however, the costs of purchasing these 400 
microsampling devices are an important consideration for healthcare service provision.  This method 401 
has the potential to assist clinicians in monitoring patient adherence to prescribed drug therapy, and 402 
with that data, to optimize treatment. However, before implemention for routine therapeutic drug 403 
monitoring it will be necessary to correlate whole blood drug concentrations with plasma levels and 404 
conduct an extensive patient study.  405 
 406 
5. Acknowledgements 407 
This research did not receive any specific grant from funding agencies in the public, commercial, or 408 
not-for-profit sectors 409 
 410 
6. References 411 
[1] World Health Organization, Cardiovascular diseases (CVDs). (2017) 412 
http://www.who.int/mediacentre/factsheets/fs317/en/ (accessed 08.01 .18) 413 
 414 
[2] British Heart Foundation Statistics Database UK. Economic cost. Coronary Heart Disease, 415 
economic cost. (2015) 416 
https://www.bhf.org.uk/ (accessed 13.07.16) 417 
 418 
[3] S. Tanna, G. Lawson. Opportunities and challenges for analytical chemistry. In:  Analytical 419 
Chemistry for Assessing Medication Adherence. 1st Edition, Elsevier, New York, USA, 13-16 (2016). 420 
[4] E. Sabate, Adherence to Long – Term Therapies: Evidence for Action. Switzerland, World Health 421 
Organization. http://www.who.int/chp/knowledge/publications/adherence_report/en/ (2003) 422 
 (Accessed 13 July 2016) 423 
 424 
[5] I.M. Kronish, S. Ye, Adherence to cardiovascular medications: lessons learned and future 425 
directions, Prog Cardiovasc Dis. 55(6), (2013) 590-600.). 426 
[6] A. La Caze, G. Gujral, W.N. Cottrell, How do we better translate adherence research into 427 
improvements in patient care, Int J Clin Pharm. 36(1) (2014) 10-14. 428 
[7] Q. Yang, A. Chang, M.D. Ritchey, F. Loustalot . Antihypertensive medication adherence and risk of 429 
cardiovascular disease among older adults: A population-based cohort study. J. Am. Heart Assoc. 430 
6(6) (2017) e006056. doi:10.1161/JAHA.117.006056. 431 
 432 
[8] O. González, N. Ferreirós, M. Blanco, R. Alonso, Cardiovascular drug determination in bioanalysis: 433 
an update, Bioanalysis. 7(18) (2015) 2399-2417. 434 
[9] O. Gonzalez, R.M. Alonso, N. Ferreirós, W. Weinmann, R. Zimmermann, S. Dresen, Development 435 
of an LC–MS/MS method for the quantitation of 55 compounds prescribed in combined 436 
cardiovascular therapy, J Chromatogr B. 879(3) (2010) 243-252. 437 
[10] O. Gonzalez, G. Iriarte, E. Rico, N. Ferreiros, M. ItxasoMaguregui, R. Maria Alonso, R. Maria 438 
Jimenez, LC-MS/MS method for the determination of several drugs used in combined cardiovascular 439 
therapy in human plasma, J Chromatogr B Analyt Technol Biomed Life Sci. 878(28) (2010) 2685-2692. 440 
[11] E. Dias, B. Hachey, C. McNaughton, H. Nian, C. Yu, B. Straka, R.M. Capriol. An LC–MS assay for 441 
the screening of cardiovascular medications in human samples, J Chromatogr B. 937 (2013) 44-53. 442 
[12] S. Tanna, G. Lawson. Dried blood spot analysis to assess medication adherence and to inform 443 
personalization of treatment, Bioanalysis. 6(21) (2014) 2825-2838. 444 
[13] G. Nys, M.G.M. Kok, A.C. Servais, M. Fillet. Beyond dried blood spot: Current microsampling 445 
techniques in the context of biomedical applications. TRAC-Trends in Analytical Chemistry 97 (2017) 446 
326-332. 447 
[14] S. Tanna, G. Lawson. Analytical methods used in conjunction with dried blood spots. Anal. 448 
Methods 3 (2011) 1709-1718. 449 
[15] D. Bernieh, G. Lawson, S. Tanna. Quantitative LC-HRMS determination of selected 450 
cardiovascular drugs, in dried blood spots, as an indicator of adherence to medication. J Pharm 451 
Biomed Anal 142 (2017) 232-243. 452 
[16] G. Lawson, E. Cocks, S. Tanna. Quantitative determination of atenolol in dried blood spot 453 
samples by LC-HRMS: A potential method for assessing medication adherence, J Chromatogr B 454 
Analyt Technol Biomed Life Sci. 897 (2012) 72-79. 455 
[17] G. Lawson, E. Cocks, S. Tanna. Bisoprolol, ramipril and simvastatin determination in dried blood 456 
spot samples using LC-HRMS for assessing medication adherence, J Pharm Biomed Anal. 81-82 457 
(2013) 99-107. 458 
 [18] G. Lawson, H. Mulla, S. Tanna. Captopril determination in dried blood spot samples with LC-MS 459 
and LC-HRMS: A potential method for neonate pharmacokinetic studies, J Bioanal Biomed. 4 (2012) 460 
016-025. 461 
[19] P. Abu-Rabie, P. Denniff, N. Spooner et al. Investigation of different approaches to incorporating 462 
internal standard in DBS quantitative bioanalytical workflows and their effect on nullifying 463 
haematocrit-based assay bias. Anal. Chem. 87 (2015) 4996-5003. 464 
[20] R. De Vries, M. Barfield, N. Van de Merbel et al. The effect of hematocrit on bioanalysis of DBS: 465 
results from the EBF DBS-microsampling consortium, Bioanalysis. 5(17) (2013) 2147-2160. 466 
[21] P. Denniff, N. Spooner. Volumetric absorptive microsampling: a dried sample collection 467 
technique for quantitative bioanalysis. Anal. Chem. 86(16) (2014) 8489-8495. 468 
[22] M.G.M. Kok, M. Fillet. Volumetric absorptive microsampling: current advances and applications. 469 
J Pharm Biomed Anal 147 (2018) 288-296. 470 
[23] Draft guidance for industry: bioanalytical method validation, US Department of Health and 471 
Human Services, Food and Drugs Administration. 472 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm36473 
8107.pdf/, 2013 (accessed 15.07.16). 474 
 475 
[24] Guideline on bioanalytical method validation, European Medicine Agency, 476 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC50010477 
9686.pdf/, 2011 (accessed 15.07.16). 478 
 479 
[25] R.A. Koster, J.W.C. ALffenaar, R. Botma, B. GreiJdanus, D.J. Touw, D.R. Uges, J.G. Kosterink. 480 
What is the right blood haematocrit preparation procedure for standards and quality control 481 
samples for dried blood spot analysis? Bioanalysis. 7(3) (2015) 245-351. 482 
[26] L. Tang, P. Kebarle, Dependence of ion intensity in electrospray mass spectrometry on the 483 
concentration of the analytes in the electrosprayed solution, Anal Chem. 65(24) (1993) 3654-3668. 484 
[27] N. Spooner, P. Denniff, L. Michielson et al. A device for dried blood microsampling in 485 
quantitative bioanalysis: Overcoming the issues associated with blood hematocrit, Bioanalysis. 7 486 
(2015) 653-659. 487 
[28] P.M. De Kesel, E.W. Lambert, C.P. Stove. Does volumetric absorptive microsampling eliminate 488 
the haematocrit bias for caffeine and paraxanthine in dried blood samples? A comparative study, 489 
Analytica Chimica Acta. 881 (2015) 65-73. 490 
[29] Y. Mano, K. Kita, K. Kusano. Hematocrit-independent recovery is a key for bioanalysis using 491 
volumetric absorptive microsampling devices, Mitra™. Bioanalysis. 7(15) (2015) 1821-1829. 492 
[30] D. Bernieh. Application of microsampling methods to cardiovascular medication adherence 493 
assessment. PhD Thesis, De Montfort University, UK.  2018 494 
[31] S. Tanna, G. Lawson. Self-sampling and quantitative analysis of DBS: can it shift the balance in 495 
over-burdened healthcare systems? Bioanalysis. 7(16) (2015) 1963-1966.  496 
